Coronary Artery Disease Therapeutics Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028
Coronary Artery Disease Therapeutics Market
Coronary Artery Disease (CAD) is
a medical illness caused by damaged or diseased blood vessels that supply the
heart with blood, nutrients, and oxygen. Coronary heart disease is defined by
the accumulation of cholesterol plaque in the arteries, which causes
inflammation. The accumulation of plaque gradually narrows the coronary
arteries, reducing blood flow to the heart. Shortness of breath and chest pain
result from a decrease in blood flow to the heart, which leads to a heart
attack following total blockage.
The worldwide
coronary artery disease market is divided into two segments: therapy
and testing. The market is divided into four therapeutic categories: medicines,
surgery, cardiac rehabilitation, and angioplasty. In the near future, the
medicine sector is expected to have the greatest market share in the global
coronary artery disease market. The global coronary artery disease treatments
market is divided into four tests: cardiac catheterization, cardiac CT scan,
coronary angiography, and electrocardiogram.
The Coronary Artery Disease
Therapeutics Market is competitive and fragmented, with several main
participants. Few big firms currently dominate the market in terms of market
share. AstraZeneca Plc, Gilead Sciences, Inc, Novartis AG, Pfizer Inc, Bayer
AG, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Merck & Co., Inc,
Teva Pharmaceutical Industries Ltd, and Mylan N.V. are among the businesses
currently leading the market.
Comments
Post a Comment